Vanda Pharmaceuticals (VNDA) stock

Market cap $305M

$4.81

-2.04%

Market closed. Prices as of Thursday's close.

Quality Score

-3

Poor

In its industry

#183of 276

Biotech

Checks firing

2of 14

Transition

From 52-week high

-51.6%

Below the 200-day

NextDec 12, 2026 · In 71 days“Quimilza TM (imsidolimab) BLA for GPP under review by the FDA; PDUFA target action date of December 12, 2026”FDA decision date · 8-K, Aug 5

Cash$170M, about 4 quarters at the last year's spendingOn Jun 30 · the company says “through at least the end of 2027”

Follow VNDA's trial news. Pro members can get an alert when Vanda Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when VNDA files news on its trialsFree for 24 hours. No account needed.

Cash$170M, about 4 quarters at the last year's spendingOn Jun 30 · the company says “through at least the end of 2027”

Pipeline and cash

What's next for VNDA, and how long its cash lasts

From Vanda Pharmaceuticals’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

Dec 12In 71 days“Quimilza TM (imsidolimab) BLA for GPP under review by the FDA; PDUFA target action date of December 12, 2026”FDA decision date · 8-K, Aug 5

What it means: the date by which the FDA has said it aims to decide on the company’s application. The FDA can decide earlier, or extend the date.

Lead program: Imsidolimab · under FDA review
Another trial: Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety DisorderPhase 3 · Active · 500 people · main data estimated Dec 2026 · NCT07221578

17 more trials, 2 with data due this year, 4 more milestones and 47 filings, for Pro members.

Cash runway Jun 30 balance sheet

About 4 quarters

$170M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's own estimate is “through at least the end of 2027” (8-K, Aug 5).

For Pro members: whether the cash lasts past the FDA date, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed Feb 12, 2026)
At-the-market share sales program (S-3, filed Feb 12, 2026)

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: the amounts, and the share count against a year ago.

Insiders

CFO Kevin Patrick Moran sold 42,442 shares on Mar 2. 5 more insider trades this year.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

Get an optional alert when Mihael Polymeropoulos buys or sells

For Pro members: every trade, and Mihael Polymeropoulos’s 13 filings and quotes.

Get an optional alert before VNDA's FDA date

Free for 24 hours. No account needed. Then keep going with a free account.

See every upcoming FDA date →

Biotech dates

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

In 28 daysFDA decisionIn 28 days · FDA decisionINOInovio PharmaceuticalsINO-3107INOInovio Pharmaceuticals · $122MINO-3107Under FDA review
In 39 daysANDA decisionIn 39 days · ANDA decisionNRXPNRX PharmaceuticalsDrug not namedNRXPNRX Pharmaceuticals · $130MDrug not namedA generic, under FDA review
In 51 daysFDA decisionIn 51 days · FDA decisionCAPRCapricor TherapeuticsDrug not namedCAPRCapricor Therapeutics · $486MDrug not namedUnder FDA review

8 more FDA dates and 107 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

Quality Score

Why VNDA scores -3

PoorTransition, 2 of 14 checks firingWhat the Quality Score means

Poor is below 0. Average starts at 6, Above Average at 11, Excellent at 15, and Exceptional at 20.

+2Chart checks 2 of 14 firing right now, one point each
−2Long-term trend below a falling 200-⁠day average, down over one year

Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Growth subtractsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Run-up, Size, Dilution, Volatility, Persistence, and News.

What every line is worth, and the reason behind it, on VNDA and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 1:11 AM ET, at least 15 minutes behind. How we rank stocks.

What's next

Expected to report Wed Nov 4, after the close

After its last 4 reports it closed -12.8% on average, higher 1 of 4 times.

What would turn VNDA's score around: 7 things, for Pro members

Alert me when VNDA's Quality Score turns up

Free for 24 hours. No account needed. Then keep going with a free account.

Pro

Here is what Pro members see.

Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.

A Pro member's scanner card for AMD: the Quality Score badge, the rank in the scan and in its industry, the chart checks bar, three plain lines on its strength, notable holders, and early signs, and pills for size, volume, RSI, and short interest — A card on the scanner, shown on AMD

A Pro member's stock page for AMD: the Quality Score with its rank, the checks firing, and the reason behind it, the live price, and the chart — A stock page

The scanner a Pro member sees: every stock as a card with its Quality Score, rank, and chart checks bar, and the watchlist — The scanner

The 14 checks

VNDA has 2 of 14 checks firing

One per group is shown here.

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Averages stacked in order, price near its high.

Volume1 of 3 shown

VOL VDU U/D VOL

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

The daily range is tight against its own recent history.

Buying1 of 3 shown

OBV+CLOSE HI SPRING

Closes near the high, and buyers step in on dips.

The other 10 checks on VNDA, and all 14 on every stock.Get in free →

Also on the chart

Not scored

Shown for reference. None of these counts toward the Quality Score: in our tests on 20 years of daily prices, none of them improved it.

RSI 1437.4
Above 30, below 50.
MACD (12, 26, 9)Below signal
Crossed below its signal line 2 sessions ago.
50-day average$5.20
The price is 7.5% below it.
200-day average$6.54
The price is 26.5% below it. The 50-day is below the 200-day, since Jun 26.
ADX 1418.7
Under 25, with +DI below -DI.
Support$4.45
Swing low from Aug 6, 7.5% below the price.
Resistance$5.33
Swing high from Sep 23, 10.8% above the price.
Bollinger Bands (20, 2)Below
The bands run from $4.82 to $5.41.
Volume1.4x
Against its 20-day average, for the time of day.

Its industry

How VNDA ranks in Biotech

VNDA is #183 of 276 by Quality Score. The top three are shown with their scores, and more by name.

1KNSAKiniksa Pharmaceuticals International7/1418
2ABCLAbCellera Biologics6/1416
3OABIOmniAb9/1415
VIRVir BiotechnologyOpen for its score
VKTXViking TherapeuticsOpen for its score
VRTXVertex PharmaceuticalsOpen for its score
XENEXenon PharmaceuticalsOpen for its score
183VNDAVanda Pharmaceuticals2/14-3

When does VNDA report earnings, and what happens after?

Expected to report Wed Nov 4, after the close (in 33 days). Not yet confirmed by the company.

-20.1%-17.6%-14.1%+0.5%

Oct 29Feb 11May 6Aug 5

Reported	When	Gap	Reaction	5 sessions
Aug 5, 2026After close	After close	-8.8%	+0.5%	+2.0%
May 6, 2026After close	After close	-5.7%	-14.1%	-13.6%
Feb 11, 2026After close	After close	-3.8%	-17.6%	-17.9%
Oct 29, 2025After close	After close	-8.0%	-20.1%	-17.9%

The gap is the next open against the close before the report; the reaction is where that session closed. VNDA closed higher after 1 of its last 4. Past behavior, not a forecast.

Report dates and past reactions come from sessions that have already closed, so none of these figures move.

The company

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

533 employeesWashington, DCvandapharma.com

Pro

Every line of the score, on every stock.

Real-time prices, no delay
Every line of VNDA's score, with the points and the reason
All 14 checks on VNDA and on all 2,958 stocks
Every stock ranked, with the chart
Every filing, and optional alerts on VNDA

See all 14 checks on VNDAFree for 24 hours. No account needed. Then keep going with a free account.

Questions

Straight Answers.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.